Abstract:
The aim of this study was to prepare natamycin encapsulated lecithin/chitosan mucoadhesive nanoparticle (NPs) for prolonged ocular application. These NPs were characterized by their mean particle size 213 nm, encapsulation efficiency 73.57% with a theoretical drug loading 5.09%, and zeta potential +43. In-vitro release exhibited a biphasic drug release profile with initial burst followed by a very slow drug release. The MIC90 and zone of inhibition of NPs showed similar antifungal activity as compared to marketed suspension and free natamycin against C. albicans and A. fumigates. The ocular pharmacokinetics of NPs and marketed formulation were evaluated in NZ rabbits. The NPs exhibits significant mucin adhesion. The AUC(0–∞) was increased up to 1.47-fold and clearance was decreased up to 7.4-fold as compared to marketed suspension. The PK-PD and pharmacokinetic simulation was carried out to estimate optimum dosing regimen for good efficacy. Thus, lecithin/chitosan NPs could be considered useful approach aiming to prolong ocular residence and reduce dosing frequency of NPs
